New ways to overcome infertility problem in women of advanced reproductive age

Assisted reproductive technologies (ART) efficacy directly depends on patient reproductive age. “Poor” ovary response, diminished quality of oocytes and embryos obtained and as a result decreased ability of blastocyst nidation to decidua are obstacles to good results of ART program. Melatonin, a neuropeptide, is well-known to be deeply involved in the process of organism ageing. This hormone takes part in oxidative stress degree decreasing in ovary follicles and defends oocytes from aggression of free radicals. The aim of this study was to assess the outcome of traditional ART program with additional correction with exogenic melatonin in infertile women of advanced reproductive age. It was characteristic for infertile patients of advanced reproductive age to have sharp decrease in levels of melatonin secretion. This reflects disturbances of hypothalamo-pituitary chain of reproductive system. Additional donation of exogenic melatonin (Melaxen) in some cases of ART program potentially increases the chances of successful outcome